KRAS and pancreatic neoplasm: Our results reveal that both the overexpression of KRAS wild-type and the activation of KRAS mutations can influence the proliferation rate in murine and human pancreatic cancer cell lines, resulting in an accelerated increase in cell number, which is a common characteristic of cancer.